Calvert Investment Management Inc. Sells 303,099 Shares of Pfizer Inc. (PFE)
Calvert Investment Management Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 28.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 758,439 shares of the biopharmaceutical company’s stock after selling 303,099 shares during the period. Pfizer comprises about 1.4% of Calvert Investment Management Inc.’s portfolio, making the stock its 7th largest position. Calvert Investment Management Inc.’s holdings in Pfizer were worth $26,705,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Stelac Advisory Services LLC acquired a new stake in shares of Pfizer during the second quarter worth about $110,000. Catamount Wealth Management raised its position in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the period. Commonwealth Financial Services LLC raised its position in Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares during the period. Stuart Chaussee & Associates Inc. raised its position in Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares during the period. Finally, Financial Management Professionals Inc. raised its position in Pfizer by 21.9% in the second quarter. Financial Management Professionals Inc. now owns 5,517 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 993 shares during the period. 69.66% of the stock is currently owned by institutional investors and hedge funds.
Shares of Pfizer Inc. (NYSE:PFE) traded up 0.402% during trading on Monday, hitting $33.695. 7,889,692 shares of the company’s stock were exchanged. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39. The firm has a 50-day moving average price of $34.29 and a 200-day moving average price of $34.19. The stock has a market cap of $204.38 billion, a P/E ratio of 29.871 and a beta of 0.86.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same period last year, the company posted $0.56 EPS. The business’s revenue was up 10.9% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be paid a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.58%. Pfizer’s dividend payout ratio is presently 95.24%.
PFE has been the subject of a number of recent analyst reports. Jefferies Group reduced their price target on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, June 20th. Deutsche Bank AG restated a “buy” rating on shares of Pfizer in a research report on Wednesday, June 15th. Vetr lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price target for the company. in a research report on Tuesday, June 28th. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Finally, JPMorgan Chase & Co. set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Ten equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.